2.09
-0.03(-1.42%)
Currency In USD
| Previous Close | 2.12 |
| Open | 2.1 |
| Day High | 2.11 |
| Day Low | 1.95 |
| 52-Week High | 970.2 |
| 52-Week Low | 1.95 |
| Volume | 69,335 |
| Average Volume | 618,130 |
| Market Cap | 2.87M |
| PE | -0.22 |
| EPS | -9.44 |
| Moving Average 50 Days | 3.14 |
| Moving Average 200 Days | 85.73 |
| Change | -0.03 |
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia
GlobeNewswire Inc.
May 22, 2025 12:16 PM GMT
NEWPORT BEACH, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the completion of a Phase I strategic r
PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q
GlobeNewswire Inc.
May 14, 2025 8:30 PM GMT
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has filed its Quarterly Report on Form 10-Q (“Quarterly Report”) for the three months ended Ma
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
GlobeNewswire Inc.
May 14, 2025 12:00 PM GMT
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Secu